ArticleJournal of neuromuscular diseases2025
A model to predict the 6-Minute Walk Distance in Pompe disease.
Article in Journal of neuromuscular diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPompe disease is a rare neuromuscular disorder caused by acid alpha-glucosidase deficiency, leading to glycogen accumulation and progressive striated muscle weakness. The 6-minute walk test (6MWT) is commonly used to assess functional capacity in neuromuscular diseases but can be challenging for severely affected ambulant patients.
objectiveThis study aimed to develop and validate predictive models for 6MWT performance using simpler, less demanding tests.
methodsThis retrospective monocentric study included 74 patients with Pompe disease (712 visits) and a mean follow-up of 6.6 ± 3.8 years. Functional assessments included the 6MWT, 10-meter walk test (10mWT) which was specifically used to determine gait speed, timed tests, strength and respiratory measures, and the Motor Function Measure (MFM-32). Linear regression models were developed to predict 6MWT speed, with validation using an 80%-20% training-testing split.
resultsThe cohort had an equal male-to-female ratio, with a mean age of 54.4 ± 13.5 years. The 10mWT speed showed a strong correlation with 6MWT speed (R = 0.91, p < 0.0001), confirming its potential as a surrogate measure. The most practical predictive model included 10mWT speed, age, sex, height, and weight, achieving an adjusted R
conclusionThe 10mWT offers a robust and less exhausting alternative to the 6MWT for assessing walking capacity in Pompe disease, particularly for ambulant patients with severe mobility limitations. Its strong correlation with the 6MWT and ease of implementation support its integration into clinical practice and trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.